Medinex's (Catalist:OTX) stock is up by 9.1% over the past three months. However, the company's financials look a bit inconsistent and market outcomes are ultimately driven by long-term fundamentals, ...
Orbital’s lead preclinical candidate, OTX-201, is an investigational RNA immunotherapy designed to target CD19-positive B cells involved in autoimmune diseases. The therapy is currently in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback